Elaine Ostrander
Elaine Ostrander is a renowned geneticist and researcher in the field of canine genetics. She is best known for her significant contributions to the mapping of the canine genome, which has led to a better understanding of both canine and human health.
Early Life and Education[edit]
Elaine Ostrander was born and raised in the United States. She pursued her undergraduate studies in biology and chemistry at the University of Washington, where she developed a keen interest in genetics. She then went on to earn her Ph.D. in genetics from the Oregon Health and Science University.
Career[edit]
Following her Ph.D., Ostrander joined the Fred Hutchinson Cancer Research Center in Seattle, where she began her groundbreaking work on the canine genome. Her research has been instrumental in identifying the genetic basis for many canine diseases, which has implications for understanding similar diseases in humans.
In 1996, Ostrander moved to the National Institutes of Health (NIH), where she continues her research today. She is currently the Chief of the Cancer Genetics and Comparative Genomics Branch at the National Human Genome Research Institute (NHGRI) at NIH.
Contributions to Canine Genetics[edit]
Ostrander's work has significantly advanced our understanding of the canine genome. Her research has led to the identification of genes associated with various canine diseases, including cancer, hip dysplasia, and eye diseases. This work has not only improved canine health but also has implications for human health, as many of the same genes are involved in similar human diseases.
Awards and Recognition[edit]
Ostrander's contributions to the field of genetics have been widely recognized. She has received numerous awards, including the American Kennel Club Canine Health Foundation Award and the Asa Mays Excellence in Canine Health Research Award.
See Also[edit]
-
Elaine Ostrander -
The NHGRI Dog Genome Project
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
